Healthcare business Wellnex Life (ASX: WNX) has received initial conditional binding commitments of $9 million to support its proposed dual listing on the AIM sub-market of the London Stock Exchange (LSE).
After receiving significant interest from UK-based institutions and sophisticated investors, the company launched the 1:1 non-renounceable entitlement offer it had previously announced earlier this week.
The entitlement offer is not conditional on the AIM listing being completed.
Wellnex Life chief executive officer George Karafotias said the lead brokers would continue the marketing and book building processes for the placement until the entitlement offer closes on 26 February.
The company plans to complete the issue of ordinary shares from the placement and the conversion of the notes soon after that, so as to coincide with the proposed AIM listing.
Wellnex will use the funds raised to redeem the balance of convertible notes, pay the outstanding deferred consideration for the company’s Pain Away acquisition and fund general working capital.
“Recapitalising the balance sheet by settling the outstanding deferred consideration for Pain Away and eliminating the convertible notes will save the company $1.4m annually and provide a strong platform for revenue growth in domestic and international markets,” Mr Karafotias said.
At the same time, the company is aiming to accelerate the launch of its brands in the UK and other identified European markets and pursue additional distribution of its liquid softgel range with its current and newly identified partners.
“This is a pivotal and transformative period for the company that we expect will enhance both company and shareholder value.”
Wellnex Life achieved a breakthrough earlier this month, with a new market authorisation (MA) granted for its liquid paracetamol-plus-caffeine soft gel.
The MA comes after Wellnex made a successful submission to Australia’s Therapeutic Goods Administration for the latest addition to its range of liquid soft gels.
It adds to the company’s previous MAs for liquid paracetamol, liquid paracetamol-plus-ibuprofen and liquid mini-ibuprofen.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。